コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 umor), and hypertension (in the patient with pheochromocytoma).
2 inal, catecholamine-secreting paraganglioma (pheochromocytoma).
3 inhibitors for treatment of PTEN loss-driven pheochromocytoma.
4 ing tumor, testosterone-secreting tumor, and pheochromocytoma.
5 y (range, 25-68 y), with known or suspected pheochromocytoma.
6 riteria to distinguish benign from malignant pheochromocytoma.
7 o renal cell carcinoma, hemangioblastoma and pheochromocytoma.
8 ted tomography (CT) is useful for localizing pheochromocytoma.
9 o image adrenergic innervation and suspected pheochromocytoma.
10 approach for adrenalectomy in the setting of pheochromocytoma.
11 ns the treatment of choice for patients with pheochromocytoma.
12 mangioblastoma, renal cell carcinoma, and/or pheochromocytoma.
13 or formation in patients with MEN 2A-related pheochromocytoma.
14 an chromosome 1p that is implicated in human pheochromocytoma.
15 s an inherited cancer syndrome that includes pheochromocytoma.
16 h tumorigenesis in hereditary, MEN 2-related pheochromocytoma.
17 nderlying the pathogenesis of MEN 2A-related pheochromocytoma.
18 ecially in neuroblastoma, paraganglioma, and pheochromocytoma.
19 y analyses of human DCSV purified from human pheochromocytoma.
20 peutic target in the treatment of metastatic pheochromocytoma.
21 sis and localization of benign and malignant pheochromocytomas.
22 r pathways that may be involved in malignant pheochromocytomas.
23 ith the clinical and pathologic groupings of pheochromocytomas.
24 marker for detection of benign and malignant pheochromocytomas.
25 ients underwent laparoscopic resection of 81 pheochromocytomas.
26 f a minimally invasive approach for sizeable pheochromocytomas.
27 VHL gene deletion in all four MEN 2A-related pheochromocytomas.
28 ous system, renal clear cell carcinomas, and pheochromocytomas.
29 in the tumorigenesis of some MEN 2A-related pheochromocytomas.
30 nical Cushing syndrome and less likely to be pheochromocytomas.
31 1195 shows high and specific accumulation in pheochromocytomas.
32 articularly in patients with large tumors or pheochromocytomas.
39 p)) in which Lmx1b was only deleted in Pet1 (pheochromocytoma 12 ETS factor-1)-expressing 5-HT neuron
40 2 receptor in the survival of neurons: PC12 (pheochromocytoma 12) cells and dorsal root ganglion neur
41 my were functional tumors in 43 patients (20 pheochromocytomas, 13 Cushing disease or syndrome, and 1
43 5.1 vs 3.3 cm, respectively; P < .001), more pheochromocytomas (24 of 70 [35%] vs. 100 of 476 [21%],
44 ormed genome-wide expression profiling of 58 pheochromocytomas (29 benign and sporadic, 16 benign and
45 009) and a significantly lower prevalence of pheochromocytoma (4.3% [1 of 23] vs 19.6% [22 of 112]) (
46 following nerve growth factor stimulation of pheochromocytoma 6 (PC6) cells, Rit silencing selectivel
47 maging studies suggested that the mass was a pheochromocytoma, a cortical adrenal adenoma was histolo
48 previously identified in neuroblastomas and pheochromocytomas all fail to activate CN or stimulate D
50 idence for two novel susceptibility loci for pheochromocytoma and adds a recessive digenic trait to t
51 Some germline VHL mutations cause familial pheochromocytoma and encode proteins that preserve their
53 line mutations of these genes cause familial pheochromocytoma and other neural crest-derived tumors.
54 lication of new PET radiopharmaceuticals for pheochromocytoma and paraganglioma (collectively named P
55 ck Squamous Cell Carcinoma (HNSC) tumors and Pheochromocytoma and Paraganglioma (PCPG) tumors into di
56 s with metastatic or unresectable (advanced) pheochromocytoma and paraganglioma (PPGL) have poor prog
57 Leigh syndrome and hereditary tumors such as pheochromocytoma and paraganglioma (PPGL), renal cell ca
59 MDH2 has been recently identified as a novel pheochromocytoma and paraganglioma susceptibility gene.
60 y higher average SUV(mean) was seen for both pheochromocytoma and paraganglioma than for healthy adre
64 eta missense mutations in neuroblastomas and pheochromocytomas and an acquired loss-of-function mutat
65 he sensitivity of (18)F-DOPA PET for adrenal pheochromocytomas and extraadrenal abdominal paraganglio
66 dopa also improves (18)F-DOPA PET of adrenal pheochromocytomas and extraadrenal paragangliomas is unk
69 comprehensive molecular characterization of pheochromocytomas and paragangliomas (PCCs/PGLs), a rare
73 ysis was to evaluate (18)F-flubrobenguane in pheochromocytomas and paragangliomas and to investigate
79 change the diagnostic paradigm in suspected pheochromocytomas and paragangliomas because of its homo
80 ermore, we assessed whether the genotypes of pheochromocytomas and paragangliomas correlate with the
82 ng modality for the detection and staging of pheochromocytomas and paragangliomas in different genoty
83 Newly uncovered are 7 of 63 (11%) malignant pheochromocytomas and paragangliomas in SDHA and TMEM127
85 between the microarray profiles of malignant pheochromocytomas and several known molecular pathways a
86 the FP/TMEM127 gene in 990 individuals with pheochromocytomas and/or paragangliomas, including 898 p
89 ed microarray expression analysis on benign (pheochromocytomas) and malignant (medullary thyroid carc
92 tumors, such as neuroblastoma, paraganglioma/pheochromocytoma, and carcinoids; and discuss approaches
93 d using three types of cells: neuroblastoma, pheochromocytoma, and Ewing's sarcoma family of tumors (
95 of neural progenitor cells of neuroblastoma, pheochromocytoma, and surrogate stem cell lineages from
96 patients with pancreatic NETs had associated pheochromocytomas, and 22 (88%) had no or mild pancreati
98 as of the retina and central nervous system, pheochromocytomas, and clear cell renal carcinoma, which
99 pancreatic neuroendocrine tumors and cysts, pheochromocytomas, and cystadenomas of the reproductive
101 registrants without mutations in the classic pheochromocytoma- and paraganglioma-associated genes (63
107 s, loss of pVHL function may be causative in pheochromocytoma-associated hypercatecholaminemia and ar
109 mutations of FP/TMEM127 were associated with pheochromocytoma but not paraganglioma and occurred in a
110 ne potential (MMP) and ATP level in neuronal pheochromocytoma cell (PC12) models of oxidative and nit
114 e recombinant human alpha1 I domain, the rat pheochromocytoma cell line (PC12), and the rat glioma Ru
117 kin 5 promote neurite extension of the PC-12 pheochromocytoma cell line; this effect is abolished by
121 perform studies in a continuous chromaffin (pheochromocytoma) cell line, such as PC12, although such
122 ss of this transmitter-based prosthesis, rat pheochromocytoma cells (PC12 cell line) were grown on th
123 nstrated that nerve growth factor-primed rat pheochromocytoma cells (PC12) and explanted rat dorsal r
125 PAI-1 was prominently expressed in PC12 pheochromocytoma cells and bovine adrenomedullary chroma
126 that IGF-1 was able to induce HIF-1alpha in pheochromocytoma cells and cultured neurons as well as i
129 the identification of unique sections of rat pheochromocytoma cells exposed to the sample surface dur
130 th growth and differentiation of rat adrenal pheochromocytoma cells for sustained periods in culture.
131 nervous systems, and our previous data with pheochromocytoma cells implicate Rit signaling in NGF-in
132 easured this intermediate in clonal PC12 rat pheochromocytoma cells incubated with various concentrat
133 ce mediated knock-down of NPCD expression in pheochromocytoma cells inhibits NGF-induced neuronal pro
134 growth factor-NGF) signaling systems in PC12 pheochromocytoma cells that resulted in a translocation
135 ould coassemble with native P2X2 subunits in pheochromocytoma cells to form light-activated heteromer
136 of isofuranodiene towards rat neuronal PC-12 pheochromocytoma cells were determined by MTT assay, whi
141 e yeast model paralleled those from neuronal pheochromocytoma cells, where disruption of microtubules
152 ing gene FP/TMEM127 in familial and sporadic pheochromocytomas consistent with a tumor suppressor eff
158 mean follow-up of 57 months, a contralateral pheochromocytoma developed in four patients with MEN 2 (
160 expressed genes between benign and malignant pheochromocytomas distinguish between these tumors with
161 node metastases, an aortic dissection, and a pheochromocytoma; each of these findings was seen in one
164 rage (18)F-DOPA uptake by paragangliomas and pheochromocytomas, expressed as a tumor-to-liver ratio,
166 has been in clinical use for the imaging of pheochromocytoma for many years, a large multicenter eva
172 sis defect in the major hereditary groups of pheochromocytoma have provided a mechanistic basis for t
173 Importantly, insights into the biology of pheochromocytomas have provided clues on pathway interac
178 uanidine (MIBG) analog, for the detection of pheochromocytoma in a preclinical in vivo model of endog
179 to-oncogene cause familial predisposition to pheochromocytoma in multiple endocrine neoplasia type II
181 indicated the presence of paragangliomas and pheochromocytomas in 68 patients and the absence of a tu
183 e outcomes of laparoscopic adrenalectomy for pheochromocytomas in the largest study to date when perf
186 tion of a high rate of germline mutations in pheochromocytomas indicate that their genetic diversity
192 4 neuroblastoma or metastatic paraganglioma/pheochromocytoma (MP) were treated using an institutiona
193 B or the synprint deletion mutant into mouse pheochromocytoma (MPC) cell line 9/3L, a cell line that
195 ied, including patients with newly diagnosed pheochromocytoma (n = 29), patients with previously surg
196 ), patients with previously surgically cured pheochromocytoma (n = 31), healthy control subjects (n =
198 88% for the detection of paragangliomas and pheochromocytomas on a patient basis (positive and negat
199 tic angioma, one patient had an extraadrenal pheochromocytoma, one patient had an abscess in the ilio
200 radic VHL-related tumor types, as </= 10% of pheochromocytoma or early-onset renal cell carcinoma and
201 ith a prior history of primary or metastatic pheochromocytoma or paraganglioma and 69 with suspected
202 ytoma or paraganglioma and 69 with suspected pheochromocytoma or paraganglioma based on symptoms of c
204 ethods: Twenty-three patients with suspected pheochromocytoma or paraganglioma underwent PET/CT or PE
209 omide in patients with metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors.
210 udinally followed up European-American-Asian Pheochromocytoma-Paraganglioma Registry for prevalence o
212 gliomas (HNP) are very often associated with pheochromocytoma-paraganglioma syndromes, which are caus
215 eir relatives to clinically characterize the pheochromocytoma/paraganglioma diseases associated with
216 The majority of patients with metastatic pheochromocytoma/paraganglioma who presented with a prim
217 nd that patients who present with metastatic pheochromocytoma/paraganglioma with primary tumor develo
218 g a predisposition for renal cell carcinoma, pheochromocytoma/paraganglioma, cerebral hemangioblastom
219 cular types of neuroendocrine tumors such as pheochromocytomas, paragangliomas, and the adrenocortica
220 n proven to be a highly sensitive method for pheochromocytomas/paragangliomas (PHEOs/PGLs) associated
222 plex, subunit B, mutation-related metastatic pheochromocytomas/paragangliomas using (68)Ga-DOTATATE P
224 HL, suggesting that both genes contribute to pheochromocytoma pathogenesis in a subset of tumors.
225 n a review of electrocardiograms obtained on pheochromocytoma patients (n = 650) treated at our insti
228 ry for patients with biochemical evidence of pheochromocytoma, patients with tumors greater than 6 cm
229 ctate, Hoechst 33342, and FITC dyes upon the pheochromocytoma PC-12 cells and RAW 264.7 macrophages.
230 Evans rats, and cultured differentiated rat pheochromocytoma PC-12 cells, are analyzed before and af
233 c signaling using clones of undifferentiated pheochromocytoma (PC-12) cells that stably overexpress t
236 egated and fibrillar Abeta, and protects rat pheochromocytoma PC12 cells from Abeta toxicity, without
243 al as positive or negative regulators in rat pheochromocytoma (PC12) and fibroblast (normal rat kidne
246 amperometric measurements of exocytosis from pheochromocytoma (PC12) cells between two types of elect
248 ined their level and mode of toxicity on rat pheochromocytoma (PC12) cells in both differentiated and
250 inst cytochrome c-induced apoptosis in naive pheochromocytoma (PC12) cells, but were remarkably effec
251 olanzapine also provided neuroprotection to pheochromocytoma (PC12) cells, SH-SY5Y neuroblastoma cel
262 py-free interval in patients with metastatic pheochromocytomas (PCCs) and paragangliomas (PGLs).
266 tification of unique molecular signatures in pheochromocytomas (PHEOs) and paragangliomas (PGLs).
267 enesis of the most aggressive and metastatic pheochromocytomas (PHEOs) and paragangliomas (PGLs).
268 ereas specific point mutations predispose to pheochromocytoma, polycythemia, or combinations of heman
269 ested most prominently in the development of pheochromocytoma, prompting an analysis of genes and loc
270 iated with Pten heterozygosity, specifically pheochromocytoma, prostatic intraepithelial neoplasia, a
271 roendocrine cell line PC12, derived from rat pheochromocytoma, provides an example of how one canonic
272 with neuroblastoma and 5 with paraganglioma/pheochromocytoma) received 148-444 MBq (4-12mCi) of (18)
275 ptake (average SUV(max) < 6) was observed in pheochromocytoma, renal cell, differentiated thyroid, ad
277 tudy characterizing the cardiac phenotype in pheochromocytoma showed that cardiac involvement was fre
278 OH) within both sporadic and MEN2-associated pheochromocytomas, suggesting that they may contribute t
279 ne MAX mutations in patients with hereditary pheochromocytoma supports the predominant role of MAX as
283 vine adrenomedullary chromaffin cells, human pheochromocytoma tissue, PC12 pheochromocytoma cells, an
284 cularly those with the carcinoid syndrome or pheochromocytoma, to undergo surgery safely, with minima
285 lar hemangioblastomas, renal carcinomas, and pheochromocytomas typical of classical VHL syndrome were
286 the largest series of patients with familial pheochromocytoma undergoing adrenalectomy during the lap
287 rized the cardiac phenotype in patients with pheochromocytoma using cardiac magnetic resonance (CMR).
290 A or (18)F-FDG PET/CT for known or suspected pheochromocytoma were reviewed retrospectively to determ
292 anced CT can safely be used in patients with pheochromocytoma who are not receiving alpha- or beta-bl
294 m-based array identified a total of 18 of 62 pheochromocytomas with LOH within the chromosome 2 regio
296 shared activation of the hypoxic response in pheochromocytomas with mutations in VHL and SDH genes an
297 diagnosis, treatment, and pathophysiology of pheochromocytoma, with the objective of developing new g